Duocarmycin ADCS showing improved in vivo antitumor activity

Inventors

DOKTER, Willem • GOEDINGS, Peter Johannes • Verheijden, Gijsbertus Franciscus Maria • Beusker, Patrick Henry

Assignees

Byondis BV

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-9421278-B2

Patent

Publication Date

2016-08-23

Expiration Date


Abstract

The present invention relates to duocarmycin-containing antibody-drug conjugates (ADCs) for use in the treatment of human solid tumors and haematological malignancies expressing HER2, in particular breast cancer, gastric cancer, bladder cancer, ovarian cancer, lung cancer, prostate cancer, pancreatic cancer, colorectal cancer, head and neck squamous cell cancer or osteosarcoma, and acute lymphoblastic leukaemia. In particular, the present invention relates to duocarmycin-containing ADCs for use in the treatment of human solid tumors with HER2 IHC 2+ or 1+ and HER2 FISH negative tissue status. Advantageously, the present invention relates to duocarmycin-containing ADCs for use in the treatment of triple negative breast cancer (TNBC).

Core Innovation

Disclosed are duocarmycin-containing HER2-targeted antibody-drug conjugates (ADCs) defined by a structure including an anti-HER2 antibody or fragment together with linker features characterized by variable ranges, including n, an average drug-to-antibody ratio (m/DAR), and substituent groups including R1, R2, and y. The disclosed compounds include specific variable ranges for the linker-related features and for y, with indicated preferred ranges for y.

The document describes intended therapeutic use of the disclosed duocarmycin ADCs for HER2-expressing solid tumors and hematological malignancies, emphasizing treatment of tumors with HER2 IHC 2+ or 1+ and/or HER2 FISH-negative status. The disclosed examples and discussion specifically highlight triple negative breast cancer as a context for treatment, including reference to HER2 expression levels in evaluated models.

The disclosed duocarmycin ADCs, including examples such as SYD985, are argued to show unexpectedly improved in vivo antitumor activity versus trastuzumab and T-DM1, with the largest improvement reported in the lowest HER2-expression models. The document describes a patient-derived xenograft evaluation approach and provides in vivo study designs and a first-in-human clinical trial context.

Claims Coverage

Two independent claims are identified. They cover (i) a method of treating triple negative breast cancer in a human patient with a specified structured compound having a defined average DAR range, and (ii) a variant relating to intravenous infusion suitability of the pharmaceutical composition used in the method.

Treating triple negative breast cancer using a duocarmycin-containing ADC with an average DAR of 2.5-2.9

Administering to a human patient a therapeutically effective amount of a compound having the structure in which 2.5-2.9 represents an average DAR for the compound.

Intravenous infusion-suitable pharmaceutical composition

The method wherein the pharmaceutical composition is suitable for intravenous infusion.

The independent claims are directed to administering a therapeutically effective amount of a structured HER2-targeted duocarmycin-containing compound characterized by an average DAR of 2.5-2.9 for treating triple negative breast cancer, with a method variant in which the pharmaceutical composition is suitable for intravenous infusion.

Stated Advantages

Unexpectedly improved in vivo antitumor activity versus trastuzumab and T-DM1, with the largest improvement reported in the lowest HER2-expression models.

Documented Applications

Treatment of triple negative breast cancer in a human patient using the disclosed duocarmycin-containing HER2-targeted ADC compounds.

Evaluation of disclosed compounds in patient-derived xenograft (PDX) models, with comparisons to trastuzumab and T-DM1 and with reference to in vivo study designs.

A first-in-human Phase I clinical trial context is described for the disclosed approach (NCT02277717 is mentioned).

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.